Clinical Trials Browser

Breast Carcinoma In Situ × Gels × 90 days × Clear all

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

Breast Carcinoma In Situ, Breast Neoplasms